Analytical Data
-
基因名
Insulysin/IDE
- Application
-
别名
Insulysin; Insulin Protease; Abeta-degrading protease; Insulinase
-
种属
Human
-
表达系统
E. coli
-
标签
N-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P14735
-
表达区间
Ala753~Pro973
-
分子量
30kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Insulysin, also known as insulin-degrading enzyme (IDE), is a zinc-dependent metalloprotease primarily involved in the degradation of insulin and other peptide hormones. Its role in glucose homeostasis and insulin sensitivity has made it a critical target for research related to diabetes and metabolic disorders. Over the years, studies have shown that IDE not only regulates insulin levels but may also modulate the clearance of amyloid-beta peptides, implicating it in neurodegenerative diseases like Alzheimer’s. The ability of IDE to degrade multiple substrates underscores its significance in various physiological processes. The development of recombinant IDE proteins has advanced our understanding of its structure, function, and regulatory mechanisms, allowing researchers to study its activity and inhibition in more detail. Such studies are vital for exploring therapeutic strategies aimed at manipulating IDE activity to improve insulin sensitivity or reduce amyloid accumulation in the brain. As a result, IDE is emerging as a promising target for novel treatments for both metabolic syndromes and neurodegenerative diseases, highlighting the need for further investigation into its enzymatic properties and potential as a biomarker.
